Atai Life Sciences N.V. (NASDAQ: ATAI) is -58.45% lower on its value in year-to-date trading and has touched a low of $2.60 and a high of $11.92 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ATAI stock was last observed hovering at around $2.92 in the last trading session, with the day’s gains setting it 0.25%.
Currently trading at $3.17, the stock is 7.83% and 0.47% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.58 million and changing 8.56% at the moment leaves the stock -23.49% off its SMA200. ATAI registered -70.78% loss for a year compared to 6-month loss of -17.45%.
The stock witnessed a 4.97% gain in the last 1 month and extending the period to 3 months gives it a -34.91%, and is 10.45% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.90% over the week and 8.28% over the month.
Atai Life Sciences N.V. (ATAI) has around 81 employees, a market worth around $479.62M and $0.40M in sales. Distance from 52-week low is 21.92% and -73.41% from its 52-week high. The company has generated returns on investments over the last 12 months (-35.00%).
Atai Life Sciences N.V. (ATAI) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Atai Life Sciences N.V. (ATAI) is a “Buy”. 12 analysts offering their recommendations for the stock have an average rating of 1.80, where 0 rate it as a Hold and 0 think it is a “Overweight”. 12 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
The EPS is expected to shrink by -9.00% this year
Atai Life Sciences N.V. (ATAI) Top Institutional Holders
The shares outstanding are 156.61M, and float is at 150.49M with Short Float at 3.63%.
Atai Life Sciences N.V. (ATAI) Insider Activity
The most recent transaction is an insider purchase by Apeiron Investment Group Ltd., the company’s 10% Owner. SEC filings show that Apeiron Investment Group Ltd. bought 21,900 shares of the company’s common stock on Apr 29 at a price of $4.47 per share for a total of $97801.0. Following the purchase, the insider now owns 1.8 million shares.
Atai Life Sciences N.V. disclosed in a document filed with the SEC on Apr 28 that Apeiron Investment Group Ltd. (10% Owner) bought a total of 34,700 shares of the company’s common stock. The trade occurred on Apr 28 and was made at $4.46 per share for $0.15 million. Following the transaction, the insider now directly holds 1.78 million shares of the ATAI stock.
Still, SEC filings show that on Apr 27, Apeiron Investment Group Ltd. (10% Owner) acquired 19,803 shares at an average price of $4.64 for $91939.0. The insider now directly holds 1,742,702 shares of Atai Life Sciences N.V. (ATAI).
Atai Life Sciences N.V. (ATAI): Who are the competitors?
The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading 10.16% up over the past 12 months and Novan Inc. (NOVN) that is -83.48% lower over the same period. Biogen Inc. (BIIB) is 19.40% up on the 1-year trading charts.